AVGO is trading up +2.91% at $357.40 during regular market hours, versus the prior session close of $347.30. The primary catalyst is a report that Broadcom is discussing a financing package of up to $100 billion to help AI customers such as Anthropic secure more compute capacity.

ASTS is trading down -6.41% to about $58.69 versus its prior close of $62.71, with the decline occurring during regular market hours. Primary catalyst: multiple law firms announced and reiterated securities class actions alleging the company overstated its capital sufficiency and competitive lead in direct-to-cell satellite service.

NUE fell -6.13% to $248.88 during Thursday's regular session, extending a slide that began in after-hours trading following its Q3 earnings guidance. Primary catalyst: Nucor guided Q3 EPS to $5.55–$5.65, well below the FactSet consensus of $5.99, despite sequential and year-over-year improvement.

Cloudflare (NET) is down -5.73% intraday, trading near $314.80 versus a prior close of $333.94, during regular market hours. The drop follows a fresh 52-week high set in the prior session, with traders locking in gains after a sharp year-to-date rally.

XENE is trading down roughly -28.7% to $40.89 versus the prior session close of $57.35. The drop unfolded after-hours Thursday and extended into Friday's premarket, after the stock had closed the regular session up +1.04% at $57.35.

DAIC closed at $5.30, up +163.68% from the prior session's $2.01 close, with volume surging to roughly 52.5M shares versus a ~2.4M average. The rally unfolded during Thursday's regular session after SEC filings post-close Wednesday disclosed major corporate transactions.

XRTX is up +15.66% in early regular-session trading, rising to roughly $1.92 from a prior close of $1.66. The move followed the company's announcement that it plans to submit an IND for its XRx-026 gout program to the FDA in Q4 2026.

Beneficient (BENF) is up +18.65% in regular trading, climbing from a $0.629 prior close to roughly $0.75 intraday. The morning-session gain followed news of the anticipated launch of AltLens, its alternative-asset portfolio analytics and risk platform for family offices and small institutional investors.

ZTG is trading up +24.58% at $1.495 during regular session, rebounding from Tuesday's $1.20 close. The move is follow-through momentum after the company completed its acquisition of ZentoAI, expanding into AI and big data.

CPOP is up +33.33% intraday to ~$4.96, versus a $3.72 prior close, with the move extending during regular trading hours. The gain follows a 15-for-1 reverse stock split (share consolidation) effective Sept. 14, which cut shares outstanding from ~14.1 million to ~938,000.

BIAF is up +34.74% intraday, trading near $11.79 in the regular session, extending its sharp two-day rally from the prior close of $8.75. The primary catalyst is continued momentum from the newly granted Hong Kong patent for its CyPath Lung noninvasive lung-cancer diagnostic, which complements a 2025 China patent across a region with roughly 1.6 million annual lung cancer cases.

Sono Group (NASDAQ: SSM) surged +63.01% to about $2.38 from a prior close of $1.46, with the move occurring during Friday's premarket session. The jump follows a -13.61% decline in the previous session, reflecting a volatile, thinly traded micro-cap.

TNMG surged +68.03% to roughly $4.52 intraday, up from a $2.69 prior close, with the move occurring during regular market hours. The rally followed news that flagship brand The News Lens launched TNL Daily, a premium subscription newsletter, with its crowdfunding campaign exceeding 400% of its funding target.

IMCC surged +166.67%, climbing from its prior close of $1.74 to roughly $4.64, with most of the gain locked in during premarket trading (to about $4.62) before fading slightly intraday. The move was a momentum-driven, low-float speculative spike rather than a company-specific catalyst, with no major headline news behind the surge.

Planet Labs shares fell approximately 24.9% over the 30-day period ending mid-September, from a closing price of $22.62 to $16.99. The decline extends a multi-month pullback driven primarily by a valuation reset rather than deteriorating fundamentals, as revenue and profitability continued to improve.

LQDA shares traded near $68 as of mid-September 2026, down roughly 8% over the trailing 30 days, even as the stock remains sharply higher on a year-to-date basis. The pullback followed a strong second-quarter report in which revenue, net income, and YUTREPIA sales all surpassed expectations but shares still sold off.

Argan (AGX) shares fell roughly 27% over the trailing 30 days, closing at $383.00 on September 17, 2026, down from about $528 a month earlier. The decline extends a multi-month correction: the stock has shed close to half its value from its mid-2026 highs after a sharp rally tied to AI-driven power demand.

Schrödinger (SDGR) shares rose roughly 71% over the 30 days ending September 17, 2026, climbing from about $17.67 to $30.24 and reaching a new 52-week high. The rally reflects growing investor enthusiasm for AI-driven drug discovery, the launch of the Bunsen AI co-scientist, and the formation of Tectora Therapeutics.

Fabrinet (FN) shares closed at $380.92 on September 17, 2026, down roughly 21% from $482.59 one month earlier. The slide came despite record fiscal fourth-quarter results, as investors focused on heavy capital spending that pushed free cash flow into negative territory.

Okta shares climbed roughly +32% over the past 30 days, rising from a closing price of $143.92 on August 18, 2026 to $190.02 on September 17, 2026. The move was driven primarily by a stronger-than-expected fiscal second-quarter 2027 earnings report released on August 26, 2026, which beat estimates on revenue and adjusted EPS and raised full-year guidance.